Eagle Pharmaceuticals Performance
| EGRXDelisted Stock | USD 1.99 0.02 1.02% |
The firm shows a Beta (market volatility) of 0.15, which means not very significant fluctuations relative to the market. As returns on the market increase, Eagle Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Eagle Pharmaceuticals is expected to be smaller as well. At this point, Eagle Pharmaceuticals has a negative expected return of -2.98%. Please make sure to confirm Eagle Pharmaceuticals' maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Eagle Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Eagle Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 97.7 M | |
| Total Cashflows From Investing Activities | -86.8 M |
Eagle |
Eagle Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 466.00 in Eagle Pharmaceuticals on September 1, 2024 and sell it today you would lose (267.00) from holding Eagle Pharmaceuticals or give up 57.3% of portfolio value over 90 days. Eagle Pharmaceuticals is currently does not generate positive expected returns and assumes 9.0311% risk (volatility on return distribution) over the 90 days horizon. In different words, 80% of pink sheets are less volatile than Eagle, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Eagle Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eagle Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Eagle Pharmaceuticals, and traders can use it to determine the average amount a Eagle Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.3303
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EGRX |
Estimated Market Risk
| 9.03 actual daily | 80 80% of assets are less volatile |
Expected Return
| -2.98 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.33 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Eagle Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eagle Pharmaceuticals by adding Eagle Pharmaceuticals to a well-diversified portfolio.
Eagle Pharmaceuticals Fundamentals Growth
Eagle Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Eagle Pharmaceuticals, and Eagle Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Eagle Pink Sheet performance.
| Return On Equity | 0.0488 | ||||
| Return On Asset | 0.0663 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 82.05 M | ||||
| Shares Outstanding | 12.96 M | ||||
| Price To Earning | 40.52 X | ||||
| Price To Book | 0.10 X | ||||
| Price To Sales | 0.11 X | ||||
| Revenue | 316.61 M | ||||
| EBITDA | 65.48 M | ||||
| Cash And Equivalents | 36.56 M | ||||
| Cash Per Share | 2.75 X | ||||
| Total Debt | 62.47 M | ||||
| Debt To Equity | 0.23 % | ||||
| Book Value Per Share | 19.25 X | ||||
| Cash Flow From Operations | 30.8 M | ||||
| Earnings Per Share | 0.85 X | ||||
| Total Asset | 406.16 M | ||||
| Retained Earnings | 111.5 M | ||||
| Current Asset | 119.05 M | ||||
| Current Liabilities | 35.45 M | ||||
About Eagle Pharmaceuticals Performance
Evaluating Eagle Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Eagle Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Eagle Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey. Eagle Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 102 people.Things to note about Eagle Pharmaceuticals performance evaluation
Checking the ongoing alerts about Eagle Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Eagle Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Eagle Pharmaceuticals is not yet fully synchronised with the market data | |
| Eagle Pharmaceuticals generated a negative expected return over the last 90 days | |
| Eagle Pharmaceuticals has high historical volatility and very poor performance | |
| Eagle Pharmaceuticals may become a speculative penny stock | |
| Eagle Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 316.61 M. Net Loss for the year was (2.67 M) with profit before overhead, payroll, taxes, and interest of 221.67 M. | |
| Over 77.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Eagle Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Eagle Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Eagle Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Eagle Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Eagle Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Eagle Pharmaceuticals' pink sheet. These opinions can provide insight into Eagle Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Eagle Pink Sheet
If you are still planning to invest in Eagle Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eagle Pharmaceuticals' history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |